Two facets particularly relevant in T2D are (1) microbiota-derived uremic toxins contributing to renal injury [169] and (2) the interplay of incretin therapies (GLP-1) and SGLT2 inhibitors in gut and kidney functions [15,170,171]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.